Crystal structure of the conserved amino terminus of the extracellular domain of matrix protein 2 of influenza A virus gripped by an antibody

Journal of Virology

Volumn 90, Issue 1, 2016, Pages 611-615

  Cho, Ki Joon ^a,b,d   Schepens, Bert ^a,b   Moonens, Kristof ^a,c   Deng, Lei ^a,b   Fiers, Walter ^a,b   Remaut, Han ^a,c   Saelens, Xavier ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d Mogam Biotechnology Research Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX PROTEIN; MATRIX PROTEIN 2; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; M2 PROTEIN, INFLUENZA A VIRUS; PROTEIN BINDING; VIRUS ANTIBODY;

AMINO TERMINAL SEQUENCE; ARTICLE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; INFLUENZA A VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MICE, INBRED BALB C; PROTEIN BINDING; PROTEIN CONFORMATION; VIRAL MATRIX PROTEINS;

EID: 84953931575     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02105-15     Document Type: Article

References (23)

1. Krammer F, Palese P. 2015. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14:167-182. http://dx.doi.org/10.1038/nrd4529.
2. Ramos EL, Mitcham JL, Koller TD, Bonavia A, Usner DW, Balaratnam G, Fredlund P, Swiderek KM. 2015. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 211:1038-1044. http://dx.doi.org/10.1093/infdis/jiu539.
3. Lamb RA, Zebedee SL, Richardson CD. 1985. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40:627-633. http://dx.doi.org/10.1016/0092-8674(85)90211-9.
4. Fu TM, Freed DC, Horton MS, Fan J, Citron MP, Joyce JG, Garsky VM, Casimiro DR, Zhao Q, Shiver JW, Liang X. 2009. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385:218-226. http://dx.doi.org/10.1016/j.virol.2008.11.035.
5. Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, Yoshida H, Mikayama T, Kubo RT, Sarawar S, Cheroutre H, Kato S. 2008. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80:168-177. http://dx.doi.org/10.1016/j.antiviral.2008.06.002.
6. Cho KJ, Schepens B, Seok JH, Kim S, Roose K, Lee JH, Gallardo R, Van Hamme E, Schymkowitz J, Rousseau F, Fiers W, Saelens X, Kim KH. 2015. Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody. J Virol 89:3700-3711. http://dx.doi.org/10.1128/JVI.02576-14.
7. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X. 2008. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283: 11382-11387. http://dx.doi.org/10.1074/jbc. M800650200.
8. Grandea AG, III, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, Mitcham JL, Cieplak W, Stewart SM, Grantham ML, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M. 2010. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 107:12658-12663. http://dx.doi.org/10.1073/pnas.0911806107.
9. Kabsch W. 2010. XDS. Acta Crystallogr D Biol Crystallogr 66:125-132. http://dx.doi.org/10.1107/S0907444909047337.
10. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J Appl Crystallogr 40: 658-674. http://dx.doi.org/10.1107/S0021889807021206.
11. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. 2011. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67:355-367. http://dx.doi.org/10.1107/S0907444911001314.
12. Tormo J, Blaas D, Parry NR, Rowlands D, Stuart D, Fita I. 1994. Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2. EMBO J 13:2247-2256.
13. Stanfield RL, Fieser TM, Lerner RA, Wilson IA. 1990. Crystal structures of an antibody to a peptide and its complex with peptide antigen at 2.8 A. Science 248:712-719. http://dx.doi.org/10.1126/science.2333521.
14. Ghiara JB, Stura EA, Stanfield RL, Profy AT, Wilson IA. 1994. Crystal structure of the principal neutralization site of HIV-1. Science 264:82-85. http://dx.doi.org/10.1126/science.7511253.
15. Serriere J, Dugua JM, Bossus M, Verrier B, Haser R, Gouet P, Guillon C. 2011. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography. J Mol Biol 405:33-42. http://dx.doi.org/10.1016/j.jmb.2010.10.033.
16. Rini JM, Stanfield RL, Stura EA, Salinas PA, Profy AT, Wilson IA. 1993. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc Natl Acad SciUSA90:6325-6329. http://dx.doi.org/10.1073/pnas.90.13.6325.
17. Ding J, Smith AD, Geisler SC, Ma X, Arnold GF, Arnold E. 2002. Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1. Structure 10:999-1011. http://dx.doi.org/10.1016/S0969-2126(02)00793-1.
18. Olal D, Kuehne AI, Bale S, Halfmann P, Hashiguchi T, Fusco ML, Lee JE, King LB, Kawaoka Y, Dye JM, Jr, Saphire EO. 2012. Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J Virol 86:2809-2816. http://dx.doi.org/10.1128/JVI.05549-11.
19. Campbell AP, McInnes C, Hodges RS, Sykes BD. 1995. Comparison of NMR solution structures of the receptor binding domains of Pseudomonas aeruginosa pili strains PAO, KB7, and PAK: implications for receptor binding and synthetic vaccine design. Biochemistry 34:16255-16268. http://dx.doi.org/10.1021/bi00050a005.
20. Dyson HJ, Cross KJ, Houghten RA, Wilson IA, Wright PE, Lerner RA. 1985. The immunodominant site of a synthetic immunogen has a conformational preference in water for a type-II reverse turn. Nature 318:480-483. http://dx.doi.org/10.1038/318480a0.
21. Blumenstein M, Matsueda GR, Timmons S, Hawiger J. 1992. A betaturn is present in the 392-411 segment of the human fibrinogen gammachain. Effects of structural changes in this segment on affinity to antibody 4A5. Biochemistry 31:10692-10698.
22. Campbell AP, Sykes BD, Norrby E, Assa-Munt N, Dyson HJ. 1996. Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125. Fold Des 1:157-165. http://dx.doi.org/10.1016/S1359-0278(96)00024-7.
23. Lovell SC, Davis IW, Arendall WB, III, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC. 2003. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins 50:437-450. http://dx.doi.org/10.1002/prot.10286.